[Associations of serum neuromarkers with clinical features of Parkinson's disease].

Autor:	Nikitina MA; Siberian State Medical University, Tomsk, Russia., Koroleva ES; Siberian State Medical University, Tomsk, Russia., Brazovskaya NG; Siberian State Medical University, Tomsk, Russia., Boyko AS; Mental Health Research Institute - Tomsk National Research Medical Center Russian Academy of Sciences, Tomsk, Russia., Levchuk LA; Mental Health Research Institute - Tomsk National Research Medical Center Russian Academy of Sciences, Tomsk, Russia., Ivanova SA; Siberian State Medical University, Tomsk, Russia.; Mental Health Research Institute - Tomsk National Research Medical Center Russian Academy of Sciences, Tomsk, Russia., Alifirova VM; Siberian State Medical University, Tomsk, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2024; Vol. 124 (4), pp. 145-152.
DOI:	10.17116/jnevro2024124041145
Abstrakt:	Objective: To evaluate the clinical and laboratory correlation of biomarkers with anti- and pro-apoptotic activity with the severity of motor and non-motor symptoms depending on the progression rate of Parkinson's disease (PD). Material and Methods: A wide range of non-motor symptoms (emotional-affective, cognitive, psychotic and behavioral disorders, fatigue, sleep disorders and autonomic disorders) was evaluated using validated scales and a number of serum neuromarkers responsible for neuroplasticity and neuronal survival processes (BDNF, PDGF, cathepsin D) in 71 patients with PD (mean age 65 (55; 70) years, disease duration 7 (4; 9) years, age of onset 57 (49; 62) years). Results: The concentration of biomarkers (BDNF, PDGF and cathepsin D) was the lowest in the group of patients with a rapid PD progression rate ( p <0.001, p =0.001 and p =0.031, respectively), the severity of motor and most non-motor symptoms was higher ( p =0.023 and p =0.001, respectively) compared to middle and slow progression rate. There were correlations between BDNF concentration and the severity of depression ( r =-0.63, p <0.001), apathy ( r =-0.48, p <0.001), impulsive behavioral disorders ( r =0.500, p <0.001), level of cognitive functions ( r =0.54, p <0.001), motor symptoms ( r =-0.43, p <0.001); between PDGF level and the severity of motor manifestations of PD ( r =-0.30, p =0.011), depression ( r =-0.70, p <0.001), apathy ( r =-0.460, p <0.001), the degree of severity of behavioral disorders ( r =0.742, p <0.001). No significant correlations were observed between the level of cathepsin D and the severity of clinical manifestations of PD, which indicates the connection of cathepsin D with the general pathogenesis of PD. Conclusion: The possibility of using serum proteins of the neurotrophin subfamily and the protein associated with autophagy, cathepsin D, as biomarkers that determine the prognosis of PD, is considered.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu